Vernon K. Sondak

Q: What Schools Are Affiliated With Vernon K. Sondak

Vernon K. Sondak is affiliated with the following schools: University of Sydney, University of Arizona, University of Michigan, University of California, Los Angeles, Wayne State University, Queen's University at Kingston, Vanderbilt University, University of South Florida, University of California, San Francisco, University of South Alabama

Vernon K. Sondak's AcademicInfluence.com Rankings

Vernon K. Sondak

Philosophy

#6616

World Rank

#9678

Historical Rank

Logic

#3757

World Rank

#4960

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Vernon K. Sondak's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Vernon K. Sondak Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Vernon K. Sondak's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Final version of 2009 AJCC melanoma staging and classification. (2009) (4419)
Molecular classification of cutaneous malignant melanoma by gene expression profiling (2000) (2062)
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017) (1458)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. (2001) (880)
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. (2000) (856)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. (2008) (648)
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. (2008) (607)
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. (2011) (519)
A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma (2004) (511)
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. (2010) (484)
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. (1996) (441)
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. (2010) (389)
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. (2011) (327)
Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model (2004) (311)
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. (2000) (304)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? (2012) (301)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy (2010) (292)
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou (2008) (278)
Cutaneous angiosarcoma of the scalp (2003) (252)
Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. (1997) (241)
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. (2004) (222)
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. (2002) (210)
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate (2002) (206)
Low recurrence rate after surgery for dermatofibrosarcoma protuberans (2004) (204)
Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. (2013) (203)
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. (2002) (202)
Chemotherapy for metastatic melanoma (2007) (192)
Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma (2003) (186)
The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma (2007) (182)
Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. (1997) (176)
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma (2013) (174)
Age-Specific Seroprevalence of Merkel Cell Polyomavirus, BK Virus, and JC Virus (2011) (170)
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma (2013) (166)
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. (2008) (164)
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms (2012) (164)
Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I) (2012) (163)
Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. (2016) (155)
Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma (2012) (153)
Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases (2013) (150)
Sentinel node biopsy and standard of care for melanoma. (2009) (149)
Dermatofibrosarcoma Protuberans: How Wide Should We Resect? (2010) (145)
Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations (1984) (140)
Systemic Therapy for Melanoma: ASCO Guideline. (2020) (137)
Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. (1997) (137)
Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. (2005) (134)
Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma (2012) (132)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. (2017) (132)
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. (2019) (124)
Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients (2014) (122)
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. (2012) (117)
Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. (2008) (115)
Beyond BRAF: where next for melanoma therapy? (2014) (112)
A brief history of melanoma: from mummies to mutations (2012) (111)
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. (2002) (111)
Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions (2003) (109)
Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. (2014) (107)
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. (2003) (106)
Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. (1995) (105)
A phase 2 trial of complete resection for stage IV melanoma (2011) (105)
Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. (2002) (104)
Multimodality management of desmoid tumors: How important is a negative surgical margin? (2008) (102)
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. (1995) (101)
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. (1999) (99)
Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma (2003) (99)
Thin primary cutaneous melanomas (2002) (96)
Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. (1993) (96)
Surgical Management of Melanoma-In-Situ Using a Staged Marginal and Central Excision Technique (2009) (93)
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy (2019) (91)
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy (2017) (89)
Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. (1985) (88)
Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified. (2010) (87)
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative (2014) (86)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial (2022) (85)
Expression of receptor tyrosine kinases epidermal growth factor receptor and HER‐2/neu in synovial sarcoma (2005) (85)
Is there a role for sentinel lymph node biopsy in the management of sarcoma? (2003) (84)
Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. (2005) (82)
Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going? (2006) (82)
Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. (2004) (82)
Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models (2014) (81)
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin): A Southwest Oncology Group Study (S0331) (2010) (81)
New Challenges in Endpoints for Drug Development in Advanced Melanoma (2011) (80)
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. (2009) (80)
Melanoma--an unlikely poster child for personalized cancer therapy. (2010) (79)
ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee. (2020) (79)
Recent Advances in Melanoma Staging and Therapy (1999) (76)
Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. (2011) (76)
Sentinel lymph node biopsy for melanoma: indications and rationale. (2009) (76)
Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 (2015) (76)
Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. (1984) (75)
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. (2015) (75)
The role of sentinel lymph node biopsy for melanoma: evidence assessment. (2006) (75)
Pros and cons of adjuvant interferon in the treatment of melanoma. (2003) (74)
Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438) (2012) (73)
Case–Control Study of Cutaneous Human Papillomaviruses in Squamous Cell Carcinoma of the Skin (2012) (73)
Clonal Architectures and Driver Mutations in Metastatic Melanomas (2014) (72)
Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies (2018) (72)
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells (2015) (72)
Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512 (2012) (71)
Targeting events in melanoma carcinogenesis for the prevention of melanoma (2006) (71)
Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience (2015) (69)
Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma (2016) (68)
Sentinel Node Biopsy is Indicated for Thin Melanomas ≥0.76 mm (2012) (68)
Sentinel node biopsy for thin melanomas: which patients should be considered? (2005) (67)
Pediatric melanoma: Analysis of an international registry (2013) (66)
Desmoplastic and neurotropic melanoma (2004) (66)
Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. (2010) (65)
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. (2019) (65)
Cutaneous Angiosarcoma: A Single-Institution Experience (2013) (64)
Case–control Study of Merkel Cell Polyomavirus Infection and Cutaneous Squamous Cell Carcinoma (2011) (63)
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. (2005) (63)
Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful? (2004) (62)
The Unique Clinical Characteristics of Melanoma Diagnosed in Children (2012) (62)
Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. (1995) (62)
A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms. (2017) (61)
Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. (2013) (61)
Inhibition of autophagy enhances the effects of the AKT inhibitor MK‐2206 when combined with paclitaxel and carboplatin in BRAF wild‐type melanoma (2014) (60)
Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. (1998) (59)
Use of Anti-phosphohistone H3 Immunohistochemistry to Determine Mitotic Rate in Thin Melanoma (2010) (59)
Radiotherapy influences local control in patients with desmoplastic melanoma (2014) (59)
Merkel Cell Carcinoma of Unknown Primary Origin (2012) (59)
Case–control study of genus‐beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma (2014) (58)
Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. (2013) (57)
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma (2018) (56)
The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. (1997) (55)
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 (2018) (55)
Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma (2015) (55)
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. (2007) (54)
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues (2008) (54)
Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics* (2014) (53)
Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma (2013) (53)
Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin – a case–control study (2012) (53)
Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. (2009) (52)
Computed tomography in staging of patients with melanoma metastatic to the regional nodes (1997) (51)
Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431) (2008) (51)
Age-related differences in breast cancer treatment (2006) (50)
Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin. (2013) (50)
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. (1998) (50)
Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. (1997) (49)
Melanoma in the brain: biology and therapeutic options (2012) (48)
Phase II Trial of Recombinant Human Interleukin‐4 in Patients with Disseminated Malignant Melanoma: A Southwest Oncology Group Study (1998) (48)
Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. (2004) (48)
Malignant melanoma: current state of primary and adjuvant treatment. (2003) (47)
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. (2019) (46)
Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma? (2009) (46)
Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection. (2013) (45)
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma (2021) (45)
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. (2020) (45)
Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. (1994) (45)
Desmoplastic Melanoma: Is There a Role for Sentinel Lymph Node Biopsy? (2013) (44)
Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node‐negative melanoma (2015) (44)
Melanoma: Adjuvant therapy and other treatment options (2003) (43)
Melacine®: an allogeneic melanoma tumor cell lysate vaccine (2003) (40)
Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma (2019) (40)
Nonsurgical Treatment Options for Basal Cell Carcinoma (2011) (39)
Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck (2017) (39)
ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee. (2020) (38)
Malignant melanoma of the foot and ankle. (1995) (38)
Treatment options for limited or symptomatic metastatic melanoma. (2008) (38)
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma (2018) (37)
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). (2017) (37)
Merkel cell carcinoma: pathologic findings and prognostic factors. (2010) (36)
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon (2010) (36)
Dermatofibrosarcoma protuberans: what is the best surgical approach? (1999) (36)
Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers (2008) (36)
Progression of cutaneous melanoma: implications for treatment (2012) (36)
The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanomas (2012) (35)
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials (2001) (35)
Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough? (2018) (34)
Adjuvant therapy for melanoma. (1997) (34)
Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma (2012) (33)
Interferon alfa-2a for melanoma metastases (2002) (32)
Modulation of Janus kinase 2 by cisplatin in cancer cells. (2004) (32)
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma (2011) (32)
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials (2018) (31)
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases (2021) (31)
Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. (2008) (30)
Case–control study of smoking and non-melanoma skin cancer (2012) (30)
Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma (2015) (29)
Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both? (2018) (29)
Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. (1996) (29)
Advances in melanoma therapy. (1998) (29)
Expression of 12-lipoxygenase as a biomarker for melanoma carcinogenesis (2002) (29)
Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. (2012) (29)
Cutaneous melanoma: methods of biopsy and definitive surgical excision (2005) (29)
High frequency of brain metastases after adjuvant therapy for high‐risk melanoma (2017) (28)
Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma: A Southwest Oncology Group Study (1993) (28)
Diagnostic procedures and pretreatment evaluation of soft tissue sarcomas. (1994) (28)
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. (2001) (27)
Neural networks and artificial intelligence (1989) (27)
Preoperative idoxuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up (1998) (27)
When will melanoma vaccines be proven effective? (2004) (27)
Retroperitoneal sarcomas (2005) (27)
Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients (2012) (26)
Identifying risk factors using a skin cancer screening program. (2013) (26)
In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. (1988) (26)
Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. (2013) (26)
Application of molecular cytogenetic techniques in a case study of human cutaneous metastatic melanoma. (2001) (26)
Complete Spontaneous Regression of Pulmonary Metastatic Melanoma (1998) (26)
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee (2020) (26)
Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2) (2021) (25)
Comparison of Single-Photon Emission Computed Tomography–Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies (2017) (25)
Stratifying SLN incidence in intermediate thickness melanoma patients. (2017) (25)
Evolution and clinical application of a rapid chemosensitivity assay (1985) (25)
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities (2019) (25)
The surgical management of primary and metastatic Merkel cell carcinoma. (2010) (24)
Adenocarcinoma in a choledochal cyst during pregnancy: a case report and guidelines for management. (1988) (24)
BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy (2016) (24)
Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. (1991) (24)
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee (2020) (23)
Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel). (2018) (23)
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. (2006) (23)
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter (2013) (23)
Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. (1997) (23)
Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin. (2012) (23)
Pediatric Melanoma and Atypical Melanocytic Neoplasms. (2016) (23)
What is the Significance of the In Transit or Interval Sentinel Node in Melanoma? (2011) (22)
Cutaneous melanoma: pathogenesis and rationale for chemoprevention. (2005) (22)
Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival (2019) (22)
Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group. (1994) (22)
Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. (2007) (22)
Soft tissue sarcomas of the extremity and retroperitoneum: advances in management. (1991) (22)
Markers and tissue resources for melanoma: meeting report. (2006) (22)
Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. (2012) (22)
Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. (2013) (21)
Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation (2016) (21)
CT of recurrent retroperitoneal sarcomas. (2000) (21)
Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects (2013) (21)
Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects (2008) (20)
Combination Therapies for Melanoma: A New Standard of Care? (2016) (20)
Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. (2017) (20)
Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. (2020) (20)
Targeted therapies: Improved outcomes for patients with metastatic melanoma (2011) (20)
Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression (2013) (20)
Management of familial melanoma and nonmelanoma skin cancer syndromes. (2009) (19)
Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference (2006) (19)
Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma (2007) (19)
A Collision of Diseases: Chronic Lymphocytic Leukemia Discovered During Lymph Node Biopsy for Melanoma (2013) (19)
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma (2010) (19)
Expression of CXCR4, E-Cadherin, Bcl-2, and Survivin in Merkel Cell Carcinoma: An Immunohistochemical Study Using a Tissue Microarray (2012) (19)
A centimeter here, a centimeter there: does it matter? (1995) (19)
Surgical therapy of cutaneous melanoma. (2007) (18)
The State of Melanoma: Emergent Challenges and Opportunities (2021) (18)
Is a Wider Margin (2 cm vs. 1 cm) for a 1.01–2.0 mm Melanoma Necessary? (2016) (18)
A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy (2004) (18)
Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival? (2020) (18)
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508 (2010) (17)
Surgical resection for stage IV melanoma: A Southwest Oncology Group trial (S9430). (2006) (17)
Completely regressed cutaneous melanocytic lesion revisited. (2009) (17)
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). (1996) (17)
Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway. (1997) (17)
State of the science 60th anniversary review (2008) (17)
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. (1999) (17)
Gender disparities in patients with melanoma: breaking the glass ceiling. (2012) (17)
A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin (2004) (17)
A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent. (2000) (16)
malignant melanoma by gene expression pro ® (16)
SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma. (2016) (16)
Melanoma margins: the importance and need for more evidence-based trials. (2004) (16)
Multidisciplinary management of special melanoma situations: Oligometastatic disease and bulky nodal sites (2007) (16)
Computers and medicine (1979) (16)
Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. (2010) (15)
Current state of treatment for primary cutaneous melanoma (2004) (15)
Early stage (I, II, III) melanoma (2001) (15)
Merkel cell carcinoma and immunosuppression: what we still need to know. (2015) (15)
Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines (2017) (15)
The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up (2012) (15)
The role of radiation therapy in the management of cutaneous melanoma. (2011) (15)
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma. (2019) (15)
Current Immunotherapy Practices in Melanoma. (2019) (15)
Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for? (2008) (15)
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma (2010) (14)
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial. (1992) (14)
Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes (2016) (14)
Novel treatments for melanoma brain metastases. (2013) (14)
In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. (2013) (14)
Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. (2016) (14)
Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma (2015) (14)
A Phase II Trial of Interleukin‐2 and Interferon‐α in the Treatment of Metastatic Colorectal Carcinoma (1995) (14)
Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy. (2022) (14)
Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. (2004) (13)
Staged margin control techniques for surgical excision of lentigo maligna. (2009) (13)
Risk-stratified screening for detection of melanoma. (2015) (13)
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (13)
Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer. (1999) (13)
Activation of T lymphocytes for the adoptive immunotherapy of cancer (1994) (12)
Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit (2019) (12)
Evaluation of interferon alpha‐2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026 (2007) (12)
Clinical application of the thymidine incorporation assay. (1987) (12)
Targeted therapy in melanoma. (2013) (12)
Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base. (2014) (12)
Soft tissue sarcomas. (2004) (12)
Higher than reported adolescent and young adult clinical trial enrollment during the “Golden Age” of melanoma clinical trials (2018) (12)
Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma. (2021) (12)
Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin (2016) (12)
Adjuvant therapy for melanoma: a surgical perspective. (2011) (12)
LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial (2021) (11)
Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. (2016) (11)
NCCN practice guidelines for occult primary tumors (1998) (11)
How does interferon work? Does it even matter? (2002) (11)
Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report (2009) (11)
Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells (2022) (11)
Unanswered questions about margin recommendations for primary cutaneous melanoma. (2012) (11)
Individualizing follow-up for patients with early-stage melanoma. (2011) (11)
Adjuvant immunotherapy for cancer: the next step. (2015) (11)
Skin cancer: Targeted therapy for melanoma: is double hitting a home run? (2013) (11)
Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial (1999) (10)
Tumor Vaccines (2002) (10)
Enhancing Effect of Interleukin 1α Administration on Antitumor Effector T-Cell Development (1991) (10)
Routine biopsy of cloquet's node is of limited value in sentinel node positive melanoma patients (2010) (10)
Indications and options for systemic therapy in melanoma. (2014) (10)
The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma (2020) (10)
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee (2020) (10)
Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy (2016) (10)
Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma (2008) (10)
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial (2022) (10)
XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation (2015) (10)
Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas (2021) (10)
Unanswered questions in the management of stage I-III Merkel cell carcinoma. (2014) (10)
Staging and prognostic factors for stage IV melanoma: Initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4,895 melanoma patients (2008) (10)
Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma (2020) (9)
Metastatic patterns of extremity liposarcoma and their outcome (2002) (9)
Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection (2021) (9)
Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions (2017) (9)
Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035 (2004) (9)
Vitamin D and Melanoma: What Do We Tell Our Patients? (2016) (9)
Chemoprevention of melanoma: theoretical and practical considerations. (2005) (9)
Extending the reach of BRAF-targeted cancer therapy (2012) (9)
Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas (2020) (9)
Sentinel lymph node biopsy in melanoma: Facts and controversies. (2010) (9)
Echoes of a failure: what lessons can we learn? (2019) (9)
Metastatic nevoid melanoma in a 41/2‐year‐old child (2003) (9)
Microsatellitosis in Patients with Melanoma (2018) (9)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer (2022) (8)
Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients. (2016) (8)
Current status of biomarkers for melanoma metastasis. (2006) (8)
Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival (2014) (8)
Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis? (2020) (8)
Testing chemotherapeutic combinations in the Human Tumor Colony--Forming Assay. (1988) (8)
Vaccine Therapy of Melanoma: An Update (2005) (8)
Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy (2019) (8)
Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508 (2008) (8)
Polyethylene wear debris presenting as a retroperitoneal tumor. (1998) (8)
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis (2021) (8)
Sarcomas of Bone and Soft Tissues (2007) (8)
Selecting Patients With Thin Melanoma for Sentinel Lymph Node Biopsy-This Time It's Personal. (2017) (8)
Integrating molecular biomarkers into current clinical management in melanoma. (2014) (7)
Genomic analysis of a case of agminated Spitz nevi and congenital‐pattern nevi arising in extensive nevus spilus (2018) (7)
Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – A Southwest Oncology Group Study (2004) (7)
SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. (2012) (7)
Lymphangiogenesis: host and tumor factors in nodal metastasis. (2008) (7)
Surgical management of melanoma. (2014) (7)
Unusual presentations of melanoma: melanoma of unknown primary site, melanoma arising in childhood, and melanoma arising in the eye and on mucosal surfaces. (2014) (7)
Adoptive cellular therapy of malignancy. (1993) (7)
Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma. (2021) (7)
Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role? (2012) (7)
Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era (2020) (6)
Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice. (2014) (6)
Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma. (2017) (6)
Are we there yet? Prolonged MAPK inhibition in BRAF(V600)-mutant melanoma. (2016) (6)
Merkel Cell Carcinoma: A Multidisciplinary Approach (2010) (6)
Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma. (2009) (6)
Preoperative multimodality treatment of large soft tissue sarcomas. How can we get more (function) from less (surgery)? (1993) (6)
Minimizing Morbidity while Preserving Outcome after Inguinal Lymphadenectomy: Navigating between Scylla and Charybdis (2011) (6)
Proper Margins of Excision in Dermatofibrosarcoma Protuberans: Wide or Narrow? (2008) (6)
Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease (2022) (6)
Point: Interferon-α for Adjuvant Therapy for Melanoma Patients (2004) (6)
Has targeted therapy for melanoma made chemotherapy obsolete? (2013) (5)
Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma (2021) (5)
Improving patient outcomes to targeted therapies in melanoma (2016) (5)
Cytoreductive surgery for melanoma. (2007) (5)
Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group Trial S0438. (2010) (5)
Diagnostic techniques for primary cutaneous melanoma. (2009) (5)
Surgical therapy of primary cutaneous melanoma. (1996) (5)
Cutaneous viral infections associated with ultraviolet radiation exposure (2020) (5)
Current and planned multicenter trials for patients with primary or metastatic melanoma (2011) (5)
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer (2011) (5)
Viruses in Skin Cancer (VIRUSCAN): Study Design and Baseline Characteristics of a Prospective Clinic-Based Cohort Study (2019) (5)
Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma? (2003) (5)
Analysis of the clinical utility of a predictive chemosensitivity assay. (1985) (5)
SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma. (2015) (5)
Meeting Report from the Third Global Workshop on Melanoma (2010) (5)
How Do We Know When a Lymph Node Dissection is Adequate? (2011) (5)
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372. (2018) (5)
BRAF-MEK inhibition in melanoma brain metastases: a new hope. (2017) (5)
Treating melanoma in adolescents and young adults: challenges and solutions (2015) (5)
Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from SWOG S0008. (2010) (5)
The sentinel lymph node: More than just another blue lymph node (2003) (5)
Inhibition of BRAF and MEK in BRAF-mutant melanoma (2015) (5)
Management of intussusception in patients with melanoma (2019) (5)
Is There a Role for Adjuvant High-Dose Interferon-α-2b in the Management of Melanoma? (2012) (5)
Current immunotherapy of melanoma (2005) (4)
A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma. (1995) (4)
The Florida Melanoma Trial I: A Prospective Multi-center Phase I/II Trial of Post-operative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-alpha in the Treatment of Advanced Stage III Melanoma (2008) (4)
Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. (2020) (4)
A Comprehensive Approach to Pediatric Atypical Melanocytic Neoplasms with Comment on the Role of Sentinel Lymph Node Biopsy. (2016) (4)
RE: A Comparison of Survival Rates for Treatment of Melanoma Metastatic to the Brain (2004) (4)
Use of adjuvant therapy in cutaneous melanoma (2001) (4)
Melanoma: MSLT-1—putting sentinel lymph node biopsy into context (2014) (4)
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. (2023) (4)
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary (2022) (4)
Abstract CT119: Trial in progress: First in human Phase I study using a plasmid DNA coding for Emm55 streptococcal antigen (IFx-Hu2.0) in patients with unresectable stage III or stage IV cutaneous melanoma (2019) (4)
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases e A multicenter cohort study (2022) (4)
Point: Interferon-alpha for adjuvant therapy for melanoma patients. (2004) (4)
Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study (2022) (4)
Sentinel Lymph Node Biopsy in Melanoma and Other Cutaneous Malignancies (2014) (4)
Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience (2018) (4)
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers (2022) (4)
The prognostic significance of lymph node metastasis in pediatric melanoma and atypical melanocytic proliferations (2013) (4)
In vitro sensitivity of breast carcinoma to combination chemotherapy. (1984) (4)
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma. (2017) (4)
Use and abuse of statistics in evidence-based medicine. (2002) (4)
Adjuvant interferon: recommit or move on? (2011) (4)
Melanoma Vaccines: Breakthrough or Bust? (2002) (4)
New directions for medical artificial intelligence (1990) (3)
Primary Tumor Thickness as a Prognostic Factor in Merkel Cell Carcinoma: The Next Big Thing? (2012) (3)
Setting the bar for adjuvant treatment of melanoma. (2014) (3)
Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma. (2020) (3)
A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study (2002) (3)
Regression is significantly associated with outcomes for patients with melanoma. (2021) (3)
Adjuvant therapy for melanoma. (2001) (3)
Resistance patterns to anti-PD-1 therapy in metastatic melanoma. (2016) (3)
Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using two sets of response criteria. (2015) (3)
Multi-institutional melanoma vaccine trial (1996) (3)
Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma (2004) (3)
Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. (2019) (3)
Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience (2018) (3)
A phase I/II trial of DTIC and dasatinib in metastatic melanoma. (2010) (3)
Refining the criteria for sentinel lymph node biopsy in patients with thinner melanoma (2010) (3)
99mTc-tilmanocept for lymphoscintigraphy (2013) (3)
At the Confluence of Radiation Therapy and Immunotherapy: External Beam Radiation (EBRT) with Intratumoral Injection of Dendritic Cells as Neoadjuvant Treatment of High-risk Soft Tissue Sarcoma Patients (2009) (3)
Nonsentinel Node Metastases in Melanoma: Do They Reflect the Biology of the Tumor, the Lymph Node or the Surgeon? (2009) (3)
Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun. (2016) (3)
Abstract CT241: Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma (2020) (3)
Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study (2021) (3)
The Contoured Staged Marginal and Central Surgical Excision Technique With En Face Histopathological Analysis: Useful Additions in the Armamentarium for Treating and Diagnosing Melanoma In Situ (2009) (2)
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy (2001) (2)
Sentinel Lymph Node Biopsy in Melanoma and Other Cutaneous Malignancies | PER (2014) (2)
Is the presence of tumor‐infiltrating lymphocytes predictive of outcomes in patients with melanoma? (2022) (2)
Abstract 809: BRAF wild-type melanoma survival hinges upon AKT activity and adaptive autophagic reprogramming in response to chemotherapy (2014) (2)
Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma. (2016) (2)
340 POSTER Gene therapy with plasmid IL-12 delivered by electroporation in patients with malignant melanoma: results of first human Phase I trial (2006) (2)
Relationships between primary tumor size , number of involved nodes and survival among 8 , 044 cases of Merkel cell carcinoma (2019) (2)
Abstract CT125: A phase III randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404 (2016) (2)
Surgical Management of Merkel Cell Carcinoma (2010) (2)
COMMENT ON: RANDOMIZED TRIAL OF ADJUVANT HUMAN INTERFERON GAMMA VERSUS OBSERVATION IN HIGH-RISK CUTANEOUS MELANOMA : A SOUTHWEST ONCOLOGY GROUP STUDY. AUTHORS' REPLY (1996) (2)
Occult primary cancer clinical practice guidelines. (2005) (2)
Enhancing effect of interleukin 1 alpha administration on antitumor effector T-cell development. (1991) (2)
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008 (2009) (2)
Surgical management of melanoma (2018) (2)
Biopsy of the Sentinel Lymph Node (2020) (2)
Genetic variations in the epidermodysplasia verruciformis (EVER/TMC) genes, cutaneous human papillomavirus infection and squamous cell carcinoma of the skin (2015) (2)
Evaluation of amonafide in disseminated malignant melanoma (1993) (2)
OP8. Economic implications of hepatic arterial infusion chemotherapy in the treatment of nonresectable colorectal liver metastases (1997) (2)
Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. (2010) (2)
The future of targeted therapy approaches in melanoma (2009) (2)
The value of sentinel lymph node biopsy in the management of head and neck melanoma (2007) (2)
Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease (2019) (2)
Erratum to: What is the Significance of the In Transit or Interval Sentinel Node in Melanoma? (2011) (2)
Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma. (2016) (2)
CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma. (2012) (2)
Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy. (1994) (2)
Chemical Therapeutics Inhibition of Wee 1 , AKT , and CDK 4 Underlies the Ef fi cacy of the HSP 90 Inhibitor XL 888 in an In Vivo Model of NRAS-Mutant Melanoma (2013) (2)
Limb-Sparing Surgery for Extremity Soft Tissue Sarcomas: Functional and Rehabilitation Considerations (1993) (2)
Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (1)
S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma. (2020) (1)
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males (2022) (1)
Vaccine Therapy for Melanoma (2011) (1)
Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissection (CLND). (2019) (1)
3347 BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria (2015) (1)
Final report of a pilot trial combining ipilimumab and adoptive cell therapy. (2017) (1)
Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. (2023) (1)
The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 (2021) (1)
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis. (2020) (1)
A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study. (1995) (1)
Radiation Therapy Influences Outcomes in Merkel Cell Carcinoma (2015) (1)
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. (2022) (1)
ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study (2022) (1)
Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes as a prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. (2010) (1)
Abstract 1881: Case-control study of sunlight exposure in basal and squamous cell carcinomas of the skin (2011) (1)
A phase III study of receptor-targeted 99mTc-tilmanocept versus blue dye in the evaluation of SLNs in breast cancer and melanoma. (2011) (1)
High-Dose-Rate Brachytherapy Re-Irradiation for Locally Recurrent Soft Tissue Sarcoma (2010) (1)
Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin – a case–control study (2012) (1)
Melanoma and human leukocyte antigen status: The missing link? (2002) (1)
Melanoma: Changes below the Surface (2005) (1)
What's new in pediatric melanoma and Spitz tumors? Pretty much everything (2021) (1)
Controversies in the Adjuvant Therapy of Melanoma: should High-dose Interferon Be Considered Standard of Care? (2006) (1)
Cutaneous melanoma: Role of lymphatic mapping and sentinel node biopsy (2001) (1)
S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma. (2021) (1)
Sentinel Lymph Node Biopsy in Patients with T1a Cutaneous Malignant Melanoma: A Multi-Center Cohort Study. (2022) (1)
Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609. (2020) (1)
An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma (2022) (1)
New Prognostic Factors in Merkel Cell Carcinoma (2010) (1)
Erratum to: Progression of cutaneous melanoma: implications for treatment (2012) (1)
Abstract 2491: Quantification of biomarker expression, phosphorylation, and mutation in cancer using TMT labeling prior to liquid chromatography-multiple reaction monitoring mass spectrometry (2014) (1)
Interferon alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026. (2004) (1)
Adjuvant high-dose interferon revisited. (2000) (1)
Melanoma and Other Cutaneous Malignancies (2003) (1)
A phase II trial of piroxantrone in disseminated malignant melanoma (2007) (1)
Growth inhibitory effect of sodium azide in chemosensitivity assays. (1987) (1)
Prediction is Difficult, Especially About the Future: Clinical Prognostic Tools in Melanoma (2016) (1)
How Well Are We Taking Care of Melanoma Patients in the USA? (2008) (1)
A prospective open label phase 3 trial of receptor-targeted 99mTc-tilmanocept for sentinel node evaluation in breast cancer and melanoma (2011) (1)
Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. (2016) (0)
Erratum to: Progression of cutaneous melanoma: implications for treatment (2012) (0)
OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases (2021) (0)
Erratum: Jeter JM, Bowles TL, Curiel‐Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18‐44. (2019) (0)
Lymphangiogenesis Induced by Surgery: A Risk for Melanoma Metastasis—Reply (2009) (0)
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and A Literature Review (2023) (0)
Advances in the understanding and treatment of melanoma -- Keystone Symposium. (2006) (0)
SNLB Guidelines, Risks, Benefits, and Predictive and Prognostic Value (2013) (0)
Reply to A. Mangla and E. Hindié. (2022) (0)
Adjuvant Systemic Therapy for High-Risk Melanoma Patients (2018) (0)
Relationship between gene expression profile and clinical outcome in malignant melanoma (2001) (0)
How much more surgery is necessary after identifying a positive lymph node in melanoma (2010) (0)
Effects of hormonal growth factors on colony formation and chemosensitivity of human tumors in agarose (1987) (0)
Abstract 2411: Intratumoral dendritic cell vaccine as neo-adjuvant immunotherapy of high-risk soft tissue sarcoma patients undergoing external beam radiation therapy (EBRT): Prospective phase I/II clinical trial (2010) (0)
Melanoma and Nonmelanoma Skin Cancer (2007) (0)
Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival? (2020) (0)
1069P Granulomatous and sarcoid-like immune adverse events following CTLA4 and PD1 blockade adjuvant therapy of high-risk melanoma: A combined analysis of ECOG-ACRIN E1609 and SWOG S1404 phase III trials (2021) (0)
IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach. (2022) (0)
Feasibility of serial biopsies of large dysplastic nevi as a melanoma chemoprevention model. (2011) (0)
Abstract 442:RASA1alteration promotes melanoma tumorigenesis (2014) (0)
Abstract CT053: Merlin_001: a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients (2023) (0)
Case–control study of smoking and non-melanoma skin cancer (2011) (0)
Differential gene expression in liposarcoma: Insight into pathways for dedifferentiation? (2012) (0)
Epidemiology, Risk Factors, and Clinical Presentation of Melanoma (2015) (0)
617 Neoadjuvant intratumoral TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma (2022) (0)
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609 (2022) (0)
Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: An analysis of 1670 high-risk patients. (2021) (0)
Difficult situations in sarcoma. Issue 2. (2000) (0)
Age-Speciﬁc Seroprevalence of Merkel Cell Polyomavirus, BK Virus, and JC Virus (cid:1) (2011) (0)
Questions in the Management of Stage I – III Merkel Cell Carcinoma (2014) (0)
88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males (2021) (0)
Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma (2022) (0)
Best practices in integrating novel agents in melanoma (2012) (0)
1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial (2021) (0)
Difficult situations in sarcoma (1999) (0)
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males (2022) (0)
Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence‐free survival (2021) (0)
Abstract 3772A: Merkel cell polyomavirus infection in Merkel cell carincoma (2010) (0)
Melanoma: Surgical approach to metastatic disease (2012) (0)
A melanoma odyssey - a conversation with Vernon Sondak about a career in melanoma treatment and research. (2014) (0)
Treating Colon Cancer With a Melanoma Vaccine? Preposterous? (2001) (0)
An 11-gene expression signature related to tumorigenesis and immunosuppression in primary cutaneous melanoma predicts sentinel lymph node metastatic status. (2022) (0)
Unknown primary tumor high-risk melanoma as a unique patient population with distinct prognosis in the adjuvant setting: An ECOG-ACRIN E1609 study analysis. (2020) (0)
Phase II trial of RO4929097 Notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933. (2012) (0)
A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331). (2009) (0)
Radiation Therapy Improves Survival With Merkel Cell Carcinoma of the Head and Neck (2016) (0)
The use of molecular testing at a diagnosis of melanoma. (2020) (0)
[Scintillation assay for evaluating chemosensitivities of human tumors--the basic principle and clinical utility]. (1985) (0)
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition (2020) (0)
Interferon alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026 (2004) (0)
Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. (2022) (0)
Management of Locally and Regionally Recurrent Melanoma (2018) (0)
Procurement of Human Melanoma Specimens for Translational Research: Practical and Legal Considerations (2008) (0)
ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma (2022) (0)
Novel Image Guided Visualization of Experimental Cellular-based Vaccines, In Vivo, during Combined Radiation/Immunotherapy Protocols (2009) (0)
Single Photon Emission CT Compared with Conventional Planar Lymphoscintigraphy for Preoperative Sentinel Node Localization in Cutaneous Malignancies (2015) (0)
ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection (2021) (0)
Where to start with systemic melanoma therapy? (2014) (0)
Abstract LB-416: Evaluation of phase 3 multicenter clinical data of receptor targeted (CD206) Tc99m-tilmanocept for sentinel node evaluation (ILM) in breast cancer and melanoma (2011) (0)
The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 (2021) (0)
Introduction: Advanced cutaneous malignancies. (2012) (0)
Atypical Fibroxanthoma: Outcomes from a Large Single Institution Series (2023) (0)
Potential for Immunotherapy in Merkel Cell Carcinoma (2010) (0)
Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments? (2010) (0)
LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival (2021) (0)
Joint melanoma meetings in Tampa enhance communication and collaboration (2012) (0)
Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins (2019) (0)
A phase III study of receptor-targeted 99mTc-tilmanocept versus blue dye in the evaluation of SLNs in breast cancer and melanoma. (2011) (0)
Surgical oncology. (1999) (0)
4 Bone Sarcoma ... Turning the Corner (2008) (0)
History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience (2022) (0)
Update on therapies for metastatic melanoma (2013) (0)
Abstract 870: Candidate SNPs in angiogenesis and lymphangiogenesis and risk of cutaneous melanoma (2011) (0)
Abstract 4835: Genetic variation inEVER1/EVER2and beta human papillomavirus infection in cutaneous squamous cell carcinoma. (2013) (0)
Did patients (pts) in OPTiM, a trial of unresectable melanoma, have truly unresectable disease?: Results from an independent review. (2015) (0)
Does Regional Radiation Therapy Impact Outcome for High-Risk, Node-Positive Cutaneous Melanoma? (2016) (0)
The Future of Melanoma Immunotherapy (2016) (0)
Pre-SN Ultrasound-FNAC for Lymph Node Metastases in Melanoma Patients: A Reply (2017) (0)
Lessons learned from clinical trials of sentinel node biopsy (2010) (0)
Factors Predicting for Local Control in Patients With Desmoplastic Melanoma (2012) (0)
Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma (2018) (0)
Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma. (2019) (0)
Pregnancy and the Use of Hormones in Melanoma Patients (2020) (0)
Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma. (2020) (0)
Allogeneic and AutologousMelanomaVaccines : Where HaveWe Been andWhereAreWeGoing ? (2006) (0)
Comparison of key sentinel node biopsy parameters for 99mTc-tilmanocept and 99mTc-sulfur colloid in melanoma (2013) (0)
Comprar Merkel Cell Carcinoma: A Multidisciplinary Approach | Vernon K. Sondak | 9781848163126 | Imperial College Press (2010) (0)
A gene-specific model for tumor progression and metastatic potential correlates with melanoma tumor thickness (2006) (0)
Abstract208: Outcomes After Combined Modality Treatment of Retroperitoneal Sarcomas (2006) (0)
Abstract B58: Sunlight exposure and overall survival in melanoma, colon cancer, and non-Hodgkin's lymphoma (2013) (0)
Detection of Copy NumberAlterations in Metastatic Melanoma by a DNAFluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization : A Southwest Oncology Group Study ( S 9431 ) (2008) (0)
Abstract 950: Merkel cell polyomavirus infection in cutaneous squamous cell carcinomas (2011) (0)
50. Dermatofibrosarcoma Protuberans (2012) (0)
Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma (2015) (0)
Progression of cutaneous melanoma: implications for treatment (2012) (0)
Dermal melanoma without a known primary: where does it fit in our current staging system? (2014) (0)
Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (0)
Abstract 3170: Identification of novel genetic alterations driving melanoma tumorigenesis. (2013) (0)
Vaccine Therapy for Patients With Melanoma (2017) (0)
87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known (2021) (0)
Melanoma Prognosis and Staging (2019) (0)
Abstract 1659: Exhaustion of autophagy-mediated cell survival underlies the pre-clinical and clinical activity of chemotherapy combined with the AKT inhibitor MK-2206 in BRAF wild-type melanoma. (2013) (0)
Melanoma Genomics—Techniques and Implications for Therapy (2008) (0)
Title Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma : a Southwest Oncology Group study (2004) (0)
A Modified p 53 Overcomes mdm 2-mediated Oncogenic Transformation : A Potential Cancer Therapeutic Agent 1 (2000) (0)
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. (2022) (0)
Melanoma Vaccines (2004) (0)
Comparative whole genome expression profiling yields a transition point for melanoma tumor progression (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Vernon K. Sondak?

Vernon K. Sondak is affiliated with the following schools:

University of Sydney
University of Arizona
University of Michigan
University of California, Los Angeles
Wayne State University
Queen's University at Kingston
Vanderbilt University
University of South Florida
University of California, San Francisco
University of South Alabama